PNPLA2 and fatty liver disease: Based on our in vivo and in vitro studies suggesting that PEG-ASNase activates ATGL in WAT, induces adipocyte lipolysis, and leads to hepatic steatosis and hepatocyte apoptosis, we hypothesized that PEG-ASNase sensitizes hepatocytes to FFA-induced toxicity.